{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain specific molecule names, IDs, or identifiers along with bioactivity metrics (IC50, Ki, Kd, EC50), numeric values, and units."}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n101,623 2-[1-(2-phenylethoxy phenoxy)-2-                                  \n                            14 nM                                         \n        phenyl]ethylimidazoline                                           \n102,588 2-[1-(2-benzyloxy phenoxy)-4-                                     \n                            82 nM                                         \n        phenyl]butylimidazoline                                           \n100,499 2-[1-(2-benzyloxy phenoxy)-2-(4-                                  \n                            2.3 nM                                        \n        methoxyphenyl)]                                                   \n        ethylimidazoline                                                  \n101,600 2-[1-(2-benzyloxy phenoxy)-2-                                     \n                             4 nM                                         \n        phenyl)ethyl imidazoline                                          \nThe assay tubes, in triplicate, receive 20 \u03bcl of 5 nM 125I]LSD, 20 \u03bcl of test Compound (10<sup>-9</sup> M to 10<sup>-5</sup> M or 10 \u03bcM mesulergine for nonspecific binding)"}
{"final_json": [{"molecule_name": "2-[1-(2-phenylethoxy phenoxy)-2-phenyl]ethylimidazoline", "protein_target_name": null, "binding_metric": null, "value": "14", "unit": "nM"}, {"molecule_name": "2-[1-(2-benzyloxy phenoxy)-4-phenyl]butylimidazoline", "protein_target_name": null, "binding_metric": null, "value": "82", "unit": "nM"}, {"molecule_name": "2-[1-(2-benzyloxy phenoxy)-2-(4-methoxyphenyl)]ethylimidazoline", "protein_target_name": null, "binding_metric": null, "value": "2.3", "unit": "nM"}, {"molecule_name": "2-[1-(2-benzyloxy phenoxy)-2-phenyl)ethyl imidazoline", "protein_target_name": null, "binding_metric": null, "value": "4", "unit": "nM"}, {"molecule_name": "125I]LSD", "protein_target_name": null, "binding_metric": null, "value": "5", "unit": "nM"}, {"molecule_name": "test Compound", "protein_target_name": null, "binding_metric": null, "value": "10<-9", "unit": "M"}, {"molecule_name": "test Compound", "protein_target_name": null, "binding_metric": null, "value": "10<-5", "unit": "M"}, {"molecule_name": "mesulergine", "protein_target_name": null, "binding_metric": null, "value": "10", "unit": "\u03bcM"}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\n101,623 2-[1-(2-phenylethoxy phenoxy)-2-                                  \n                             14 nM                                        \n        phenyl]ethylimidazoline                                           \n102,588 2-[1-(2-benzyloxy phenoxy)-4-                                     \n                            167 nM                                        \n        phenyl]butylimidazoline                                           \n100,499 2-[1-(2-benzyloxy phenoxy)-2-(4-                                  \n                             3.5 nM                                       \n        methoxyphenyl)]ethyl midazoline                                   \n101,600 2-[1-(2-benzyloxy phenoxy)-2-                                     \n                             2.5 nM                                       \n        phenyl)ethyl imidazoline                                          \nA value in the range of 1-10 nM would indicate a highly potent compound \nThe IC50 value is converted to the Ki value by the method of Cheng and Prusoff.[Cheng, Y. -C and Prusoff, Biochem. Pharmacol. 22:3099-3108, 1973]. \nInhibition of [<sup>125</sup> I]LSD binding by a test compound is indicative of affinity for the 5HT<sub>2</sub> receptor site. The molar concentration of a Compound which causes 50% inhibition of the binding of ligand is the IC<sub>50</sub>. \nInhibition of [<sup>3</sup> H]RAUW binding of 15% or more by a test compound is indicative of affinity for the \u03b12-adrenergic site. The molar concentrateion of compound which causes 50% inhibition of the binding of ligand is the IC50."}
{"final_json": [{"molecule_name": "2-[1-(2-phenylethoxy phenoxy)-2-phenyl]ethylimidazoline", "protein_target_name": null, "binding_metric": null, "value": "14", "unit": "nM"}, {"molecule_name": "2-[1-(2-benzyloxy phenoxy)-4-phenyl]butylimidazoline", "protein_target_name": null, "binding_metric": null, "value": "167", "unit": "nM"}, {"molecule_name": "2-[1-(2-benzyloxy phenoxy)-2-(4-methoxyphenyl)]ethyl midazoline", "protein_target_name": null, "binding_metric": null, "value": "3.5", "unit": "nM"}, {"molecule_name": "2-[1-(2-benzyloxy phenoxy)-2-phenyl)ethyl imidazoline", "protein_target_name": null, "binding_metric": null, "value": "2.5", "unit": "nM"}, {"molecule_name": null, "protein_target_name": "5HT2 receptor", "binding_metric": "IC50", "value": "1-10", "unit": "nM"}, {"molecule_name": null, "protein_target_name": "5HT2 receptor", "binding_metric": "IC50", "value": null, "unit": null}, {"molecule_name": null, "protein_target_name": "\u03b12-adrenergic", "binding_metric": "IC50", "value": null, "unit": null}]}
